INTRODUCTION

Dysmenorrhoea is defined as the occurrence of painful cramps of uterine origin during menstruation and is one of the most common causes of pelvic pain which affects the quality of life of women in their reproductive age, often accompanied by other biological symptoms including dizziness, fatigue, backache, headache, vomiting and diarrhoea all occurring just before or during the menstruation. It may involve various types of pain, and may also precede menstruation for several days or occur during menstruation. It has a high prevalence of worldwide and affects the majority of women of reproductive age with 2-29% having severe pain. Dysmenorrhoea represent a substantial public health burden, that exceeds all other gynaecologic complaints and is one of the leading cause of absenteeism from school and work, loss of earnings and diminished QoL but still, it is undertreated.

Dysmenorrhoea is conventionally treated with NSAIDs or oral contraceptive pills, the efficacy of which is supported by research evidence, however NSAIDs and OCPs have limitations; some women with dysmenorrhoea do not respond to NSAIDs and OCPs (with an estimated failure rate of >15% for NSAIDs); some cannot use these medications because of contraindication or adverse effects, some prefer not to use any medication. Therefore, investigation of complementary alternative treatments for dysmenorrhoea is warranted. Better management of dysmenorrhoea may not only improve women’s quality of life but also reduce their risk of developing future pain.

ABSTRACT

Background: Dysmenorrhoea is a condition characterised by severe uterine pain during menstruation with a prevalence range between 50 to 87.8%. Many drugs have been tried to alleviate dysmenorrhea in women, but adverse events occur, therefore investigation of alternative treatments for dysmenorrhoea is warranted. The objective of this study is to compare the effect of Majoon Murmakki in dysmenorrhoea (usre tams).

Materials and Methods: In a randomised standard controlled study, 45 patients of dysmenorrhea were randomly assigned to test (n=30) and control group (n=15). In test Majoon Murmakki 3gm and control group mefenamic acid 500mg two times a day was given orally from 1st to 5th days of menstruation for two consecutive cycles. The primary outcome was assessed by subjective parameters viz. pain abdomen, nausea, vomiting, low backache diarrhoea fatigue and secondary outcome assessed by objective parameters viz. visual analogue scale for pain were assessed at each follow-up and improvement in the quality of life were assessed by SF-12 questionnaire before and after treatment.

Results: Significant relief was observed in dysmenorrhoea and associated symptoms. 26 (89.7%) of the patients in test and 13 (100%) in the control group were relieved with p<0.001 in subjective parameters as the primary outcome. 26 (89.7%) of the patients in test and 13 (100%) in the control group were relieved with p<0.001 in objective parameters as the secondary outcome. Intergroup comparison shows no significant difference in improving subjective and objective parameters with p=1.00 and p=0.540 respectively.

Conclusion: Majoon Murmakki is as effective as mefenamic acid in alleviating dysmenorrhea and associated symptoms.

Key Words: Usre tams, Dysmenorrhea, Majoon Murmakki, SF 12 questionnaire, Visual analogue scale
Unani medicine plays an important role in treating various gynaecological disease, of which drugs like habbul ghar, qust, zarawand, irsa, turbud, rewand khatayi, huila, post fali amaltas, jawtri, ma ‘jūnmusakkin dard al-rahim, jawārish amber have been mentioned for the treatment of dysmenorrhoea, of these Murmakki has been selected for the treatment of dysmenorrhoea in the present study. By thorough review of Unani literature, murmakki was found to have the properties like musakkin awfāh (analgesic), muhullil awram (anti-inflammatory), muddir-i-bowl wa hayḍl (diuretic and emmenagogue), mufatīth sudād (deobstruent) among others.

Besides, recent studies show that furanose squiterpenes with analgesic activity such as furanoelemanes, furanoeudesmanes and furanogermacranes, are present in the gum resin extract of myrrh. With all these properties murr is anticipated to alleviate dysmenorrhoea and hence selected for the present study.

**MATERIAL AND METHODS**

This study was conducted in the department of Ilmul Qabalat wa Amraze Niswan, NIUM, Bengaluru from May 2019 to February 2020.

**Ethical clearance and CTRI registration number:** The institutional ethical committee approved the present study [IEC No: NIUM/IEC/2017-18/010/ANQ/02]; following which CTRI registration was accomplished vide number CTRI/2011/04/018446. After which the clinical study was carried out.

**Study design:** Single-blind randomized standard controlled trial.

**Duration of study:** One and a half year.

**Sample size:** 45
- The sample size was calculated using formula
  \[ N = \frac{2(Za-Zb) \sigma \mu}{\mu_2} \]

**Method of collection of data:**
- History Taking & Clinical examination

**Inclusion criteria:**
- Patients in the age group of 18-35 years with regular painful menstrual cycles i.e. 21-35 days with one or more associated symptoms like nausea, vomiting, low backache, diarrhoea, fatigue and VAS score >7

**Exclusion criteria:**
- Systemic Illness like HTN/DM, & H/o allergy /sensitive to NSAIDs, hormonal treatment last 2 months
- Lactating women

Treatment was subsequently started inpatient fulfilling the inclusion criteria. The test or control drug as randomised was given for 5 days from the first day of the menstrual cycle for two consecutive cycles. Assessment of subjective and objective parameters was done before, during and after treatment. Liver function test (LFT) & renal function test (RFT) were assessed pre and post-treatment for assessment of safety.

Subjective parameters studied were pain abdomen, nausea, vomiting, low Backache, fatigue, diarrhoea and objective parameters were visual analogue scale (VAS) for pain & SF-12 scale for quality of life.

**Test drug:** Murmakki (*Commiphora myrrha*) was purchased from the local market and identified by the chief pharmacist of NIUM Bengaluru. Ma’jūn was prepared with honey according to the standard method of preparation.

**Dosage:** 3 gm twice a day, orally

**Standard control:** Mefenamic acid 500 mg twice a day

**Duration of treatment:** from 1st to 5th days of menstruation for 2 consecutive cycles

**Outcome measure:**

**Primary outcome measure:**
- Relieved: Relief in ≥ 3 subjective parameters, Not Relieved: Relief in <3 subjective parameters.

**Secondary outcome measure**
- Relieved: if vas score <4 and SF-12 score >800, Not Relieved: if vas score >4 and / or SF-12 score <800

**Statistical analysis**
Descriptive and inferential statistical analysis has been carried out in the present study. Results on continuous measurements are presented on the mean ± SD (min-max) and results on categorical measurements are presented in number (%). Significance is assessed at 5 % level of significance. The Statistical software namely SPSS 22.0, and R environment ver.3.2.2 were used for the analysis of the data (Table 1,2).

**RESULTS AND DISCUSSION**

**Baseline characteristics**
**Age:** The study participants were similar in both groups concerning baseline characteristics like age, marital status, socioeconomic status, BMI, diet, lifestyle and temperament with p >0.05 (Table 01).

**Socio-economic status:** In present study maximum number of patients, 22 (52.4%) belongs to the lower middle class, 17 (40.5%), 2 (4.8%) and 1 (2.4%) belongs to upper-middle, upper and lower class respectively. (Table 01) This is similar with the reports of Rehman et al.29 in which 18(40%) belong to lower middle, 14 (33.35%),10 (20%), 3(6.7%) upper middle, upper lower and upper class respectively.
Marital status: In the present study 25 (59.5%) patients were unmarried and 17 (40.5%) were married. (Table 01)

BMI: In present study majority of the patients 23 (54.8%) had normal BMI, followed by 10 (23.8%), 8 (19%) and 1 (2.4%) were overweight, underweight and obese respectively (Table 01) Mean +SD of BMI was 22.38±3.38. (Table 01)

**Table 1: Baseline characteristics in two groups studied**

| Variables                  | Test Group (n=29) | Control Group (n=13) | Total (n=42) | P value |
|----------------------------|------------------|----------------------|--------------|--------|
| **Age in years**           |                  |                      |              |        |
| 18-25                      | 17 (58.6%)       | 9 (69.2%)            | 26 (61.9%)   | 0.513  |
| 25-35                      | 12 (41.4%)       | 4 (30.8%)            | 16 (38.1%)   |        |
| **Marital Status**         |                  |                      |              |        |
| Married                    | 13 (44.8%)       | 4 (30.8%)            | 17 (40.5%)   | 0.391  |
| Unmarried                  | 16 (55.2%)       | 9 (69.2%)            | 25 (59.5%)   |        |
| **Socio Economic Status**  |                  |                      |              |        |
| I                         | 1 (3.4%)         | 1 (7.7%)             | 2 (4.8%)     | 0.306  |
| II                        | 14 (48.3%)       | 3 (23.1%)            | 17 (40.5%)   |        |
| III                       | 13 (44.8%)       | 9 (69.2%)            | 22 (52.4%)   |        |
| IV                        | 1 (3.4%)         | 0 (0%)               | 1 (2.4%)     |        |
| **Diet**                  |                  |                      |              |        |
| Veg                       | 7 (24.1%)        | 3 (23%)              | 10 (23.8%)   | 0.150  |
| Mixed                     | 22 (75.8%)       | 10 (76.92%)          | 32 (76.2%)   |        |
| **BMI (kg/m²)**           |                  |                      |              |        |
| <18.5                     | 5 (17.2%)        | 3 (23.1%)            | 8 (19%)      | 0.049* |
| 18.5-24.9                 | 13 (44.8%)       | 10 (76.9%)           | 23 (54.8%)   |        |
| 25-29.9                   | 10 (34.5%)       | 0 (0%)               | 10 (23.8%)   |        |
| >30                       | 1 (3.4%)         | 0 (0%)               | 1 (2.4%)     |        |
| Mean± SD                  | 23.20±4.19       | 21.57±2.58           | 22.69±3.81   | 0.204  |

**The test used:** Chi-Square/Fisher Exact Test

**Table 2: Associated symptoms of dysmenorrhea in two groups studied**

| Variables            | Test Group (n=29) | Control Group (n=13) | Total (n=42) | P-value |
|----------------------|------------------|----------------------|--------------|---------|
| Nausea               | 29 (100%)        | 12 (92.3%)           | 41 (97.6%)   | 0.310   |
| Vomiting             | 16 (55.2%)       | 5 (38.5%)            | 21 (50%)     | 0.317   |
| LBA                  | 29 (100%)        | 13 (100%)            | 42 (100%)    | 1.000   |
| Diarrhea             | 11 (37.9%)       | 4 (30.8%)            | 15 (35.7%)   | 0.654   |
| Fatigue              | 27 (93.1%)       | 10 (76.9%)           | 37 (88.4%)   | 0.162   |
| Bloating             | 0 (0%)           | 0 (0%)               | 0 (0%)       | 1.000   |
| Breast Tenderness    | 7 (24.1%)        | 0 (0%)               | 7 (16.7%)    | 0.079+  |

**The test used:** Chi-square/Fisher Exact Test

**Effect of family history and parity**

In present study 38 (90.5%) patients had a positive family history of dysmenorrhea (Table 03) Similar findings were reported by Tabri N M et al. and Rehman et al. wherein the family history was present in 74% and 63.33% respectively.

In present study 30(71.4%) of the patients were nulliparous (26 of these were unmarried and 4 were married), 8 (19%) of the participants had a history of 2 live births and 4 (9.5%) had more than 2 live births (Table 03) the results are consistent with the study conducted by Fletcher et al. wherein the majority of the patients 88% are nulliparous and only 7% were parous.

**Table 3: Significant history in two groups studied**

| Variables      | Test Group (n=29) | Control Group (n=13) | Total (n=42) | P-value |
|----------------|------------------|----------------------|--------------|---------|
| **Family History** |                  |                      |              |         |
| Present        | 25 (86.2%)       | 13 (100%)            | 38 (90.5%)   | 0.258   |
| Absent         | 4 (13.8%)        | 0 (0%)               | 4 (9.5%)     |         |
| **Parity**     |                  |                      |              |         |
| NA             | 17 (58.6%)       | 9 (69.2%)            | 26 (61.9%)   |         |
| 0-2            | 9 (31%)          | 3 (23.1%)            | 12 (54.1%)   | 1.000   |
| 3-5            | 3 (10.3%)        | 1 (7.7%)             | 4 (9.5%)     |         |

**Test used:** Chi-Square/Fisher Exact Test

**Pain in abdomen**

All the patients in both the test and control group had pain in abdomen before treatment. In the 1st cycle 2 (6.9%) and 3 (23.1%) had no pain in the abdomen while 27 (93.1%) of patients in the test group and 10 (76.9%) of the patients in the control group had no relief; while In the 2nd cycle 20 (69%) in the test and 13 (100%) in the control group were relieved of pain only 9 (31%) of the patients in the test group had pain in the abdomen. In the after-treatment cycle, 6 (20.7%) and 3 (23.1%) had no pain in the abdomen while in 23(79.3%) in the test and 10 (76.9%) in control group pain reoccurred.

The test group showed improvement of 20.7% at after treatment, p=0.005 and control group showed improvement of 23.71% at after treatment, p=0.036, considered significant.

On intergroup comparison, w.r.t test group was not significant with p=1.000, suggesting that the test drug is as effective as the control in alleviating dysmenorrhea (Table 04).

**Nausea**

All the 29(100%) patients in the test group and 12 (92.3%) patients in the control group had nausea before treatment. In the 1st cycle, 17 (58.6%) and 13 (100%) patients in the test and control group respectively were relieved of nausea while 12 (41.4%) of patients in the test group had no relief;
while in the 2nd cycle 28 (96.6%) patients in the test and 13 (100%) in the control group were relieved of nausea and only 1 (3.4%) of the patients in the test group had nausea. In the after-treatment cycle, nausea was absent in all patients in the test group and 11 (84.6%) in the control group; while in 2 (15.4%) patients in control group, nausea reoccurred. The test group showed improvement of 100.00% at after treatment, \( p < 0.001 \) and the control group showed improvement of 76.9% at after treatment, \( p = 0.036 \), considered significant. On intergroup comparison, w.r.t test group showed suggestive significance with \( p = 0.091 \), suggesting that the test drug is as effective as or more superior to control in alleviating associated with dysmenorrhea (Table 04).

### Vomiting

In present study vomiting was present in 15 (51.7%) patients in the test group and 5 (38.5%) in control group before treatment. In the 1st cycle 23 (79.3%) of patients in the test and 13 (100%) of patients in the control group had relieved of vomiting; in the 2nd cycle during treatment and the after-treatment cycle all the patients 29 (100%) and 13 (100%) in the test and control group respectively were relieved of vomiting. The test group showed improvement of 51.7% with \( p = 0.001 \) and control group with 38.5% with \( p = 0.137 \) considered non-significant. On intergroup comparison w.r.t test group was not significant with \( p = 1.000 \), suggesting that the test drug is as effective as the control in alleviating vomiting associated with dysmenorrhea (Table 04).

### LBA

All the patients in both the test and control group had LBA before treatment. In the 1st cycle 10 (34.5%) and 12 (92.3%) patients were relieved of LBA, while 19 (65.5%) of patients in the test group and 1 (7.7%) of the patients in the control group had no relief. In the 2nd cycle, 22 (75.9%) in the test and 13 (100%) in the control group were relieved of LBA and only 7 (24.1%) of the patients in the test group had LBA. In the after-treatment cycle, 19 (65.5%) and 11 (84.6%) had no LBA, while in 10 (34.5%) in the test and 2 (15.4%) in control group LBA reoccurred. The test group showed improvement of 65.5%, with \( p = 0.001 \), considered highly significant, while the control group showed improvement of 84.6% and is statistically not significant with \( p = 0.137 \). On intergroup comparison, w.r.t test group was not significant with \( p = 1.000 \), suggesting that the test drug is as effective as the control in alleviating LBA associated with dysmenorrhea (Table 04).

### Diarrhoea

In the present study, diarrhoea was present in 12 (41.5%) patients in the test group and 4 (30.8%) in the control group before treatment. In the 1st cycle 27 (93.1%) patients in the test and 13 (100%) patients in the control group had relieved of diarrhoea; in the 2nd cycle during treatment and the after-treatment cycle all the patients 29 (100%) and 13 (100%) in the test and control group respectively were relieved of diarrhoea. The test group showed improvement of 41.4%, with \( p = 0.036 \), considered significant; the control group showed improvement of 30.8% after treatment with \( p = 0.137 \), statistically not significant. On intergroup comparison w.r.t test group was not significant with \( p = 1.000 \), suggesting that the test drug is as effective as the control in alleviating diarrhoea associated with dysmenorrhea (Table 04).

### Fatigue

In the present study, fatigue was present in 27 (93.1%) patients in the test group and 10 (76.9%) in the control group before treatment. In the 1st cycle, 14 (48.3%) patients in test and 12 (92.3%) of patients in the control group had relieved of fatigue; in the 2nd cycle, 23 (79.3%) patients in the test group and all the patients of the control group were relieved of fatigue. In the after-treatment cycle, 14 (48.3%) and 12 (92.3%) patients in the test and control group respectively were relieved of fatigue while in 15 (51.7%) patients in test and 1 (7.7%) in control group fatigue reoccurred. The test group showed improvement after treatment is 41.4%, with \( p < 0.001 \), statistically significant. Control group showed improvement at after treatment is 69.2% is statistically significant with \( p < 0.001 \) with paired proportion test. On intergroup comparison, w.r.t test group showed improvement is 41.4%, with \( p = 0.007 \) suggesting that the test drug is inferior to control in alleviating fatigue associated with dysmenorrhea (Table 04).

### Table 4: Assessment of subjective parameters

| Pain in Abdomen | BT | C1 | C2 | AT | % difference | P value |
|-----------------|----|----|----|----|--------------|---------|
| Test Group (n=29) |    |    |    |    |              |         |
| • Absent        | 0(0%) | 2(6.9%) | 20(69%) | 6(20.7%) | 20.7% | 0.005 |
| • Present       | 29(100%) | 27(93.1%) | 9(33%) | 23(79.3%) | -20.7% | |
| Control Group (n=13) | | | | | | |
| • Absent        | 0(0%) | 3(23.1%) | 13(100%) | 3(23.1%) | 23.1% | 0.036 |
| • Present       | 13(100%) | 10(76.9%) | 0(0%) | 10(76.9%) | -23.1% | |
| P value*        | 1.000 | 0.162 | 0.038* | 1.000 | - | |

Nausea

Test Group (n=29)
### Table 4: (Continued)

| Pain in Abdomen | BT   | C_1  | C_2  | AT   | % difference | P - value  |
|-----------------|------|------|------|------|--------------|------------|
| Absent          | 0(0%)| 17(58.6%) | 28(96.6%) | 29(100%) | 100.0%       | <0.001     |
| Present         | 29(100%) | 12(41.4%) | 1(3.4%) | 0(0%) | -100.0%      |            |
| **Control Group (n=13)** |     |      |      |      |              |            |
| Absent          | 1(7.7%) | 13(100%) | 13(100%) | 11(84.6%) | 76.9%        | 0.036      |
| Present         | 12(92.3%) | 0(0%) | 0(0%) | 2(15.4%) | -76.0%       |            |
| **P value**     | 0.310 | 0.008** | 1.000 | 0.091+ |              |            |
| **Vomiting**    |      |      |      |      |              |            |
| **Test Group (n=29)** |     |      |      |      |              |            |
| Absent          | 14(48.3%) | 23(79.3%) | 29(100%) | 29(100%) | 51.7%        | 0.001      |
| Present         | 15(51.7%) | 6(20.7%) | 0(0%) | 0(0%) | -51.7%       |            |
| **Control Group (n=13)** |     |      |      |      |              |            |
| Absent          | 8(61.5%) | 13(100%) | 13(100%) | 13(100%) | 38.5%        | 0.137      |
| Present         | 5(38.5%) | 0(0%) | 0(0%) | 0(0%) | -38.5%       |            |
| **P value**     | 0.426 | 0.153 | 1.000 | 1.000 |              |            |
| **Diarrhoea**   |      |      |      |      |              |            |
| **Test Group (n=29)** |     |      |      |      |              |            |
| Absent          | 17(58.6%) | 27(93.1%) | 29(100%) | 29(100%) | 41.4%        | 0.036      |
| Present         | 12(41.4%) | 2(6.9%) | 0(0%) | 0(0%) | -41.4%       |            |
| **Control Group (n=13)** |     |      |      |      |              |            |
| Absent          | 9(69.2%) | 13(100%) | 13(100%) | 13(100%) | 30.8%        | 0.137      |
| Present         | 4(30.8%) | 0(0%) | 0(0%) | 0(0%) | -30.8%       |            |
| **P value**     | 0.513 | 1.000 | 1.000 | 1.000 |              |            |
| **Fatigue**     |      |      |      |      |              |            |
| **Test Group (n=29)** |     |      |      |      |              |            |
| Absent          | 2(6.9%) | 14(48.3%) | 23(79.3%) | 14(48.3%) | 41.4%        | <0.001     |
| Present         | 27(93.1%) | 15(51.7%) | 6(20.7%) | 15(51.7%) | -41.4%       |            |
| **Control Group (n=13)** |     |      |      |      |              |            |
| Absent          | 3(23.1%) | 12(92.3%) | 13(100%) | 12(92.3%) | 69.2%        | <0.001     |
| Present         | 10(76.9%) | 1(7.7%) | 0(0%) | 1(7.7%) | -69.2%       |            |
| **P value**     | 0.162 | 0.007** | 0.153 | 0.007** |              |            |

**Test used:** * Chi-Square/Fisher Exact Test and **Paired Proportion test

**VAS Score**

Mean ± SD of test group before treatment 1st cycle, 2nd cycle and after treatment are 9.03±0.73, 4.90±1.11, 1.79±1.61 and 3.14±1.30 respectively, there was a statistically significant decrease in VAS score with p-value <0.001 in the first cycle and continued till after treatment cycle with p<0.001, considered highly significant. Similarly, in control group mean ± SD before treatment 1st cycle, 2nd cycle and after treatment are 8.77±0.93, 3.23±1.59, 0.00±0.00 and 2.77±1.64 respectively, there was a statistically significant decrease in VAS score with p-value <0.001 in the first cycle and continued till after treatment cycle with p<0.001, considered highly significant. The intergroup comparison w.r.t test group after treatment there was no significant difference with p=0.439; suggesting that test drug is as effective as the control in improving the VAS scores in dysmenorrhea (Table 05). The effect of the test drug on VAS score in the present study is comparable with the studies conducted by Kannan P et al.34 with treadmill exercise, Azima S et al.21 with massage therapy and exercise, Harada et al.35 using low dose oral contraceptives, Molins Cubero et al.23 evaluating pain perception after pelvis manipulation, Mingxio et al.13 with moxibustion, Molouk et al.20 with cinnamon, Yasemin et al.36 with the intervention of diet, Rehman et al.29 using *Rheum emodi*, Asma et al.22 with *Ferula asafoetida* showed similar outcome with p=<0.001.
Table 5: VAS score- A comparison in two groups of patients studied

| VAS score | Test Group | Control Group | Total  | P-value |
|-----------|------------|---------------|--------|---------|
| RESULTS  |            |               |        |         |
| • BT      | 9.03±0.73  | 8.77±0.93     | 8.95±0.79 | 0.323   |
| • C2      | 4.90±1.11  | 3.23±1.59     | 4.38±1.48 | <0.001**|
| • AT      | 1.79±1.61  | 0.00±0.00     | 1.24±1.57 | <0.001**|

P VALUE BT

|          | C1         | C2         | AT         |
|----------|------------|------------|------------|
|          | <0.001**   | <0.001**   | <0.001**   |

The test used: Student t-test

SF-12

Mean ±SD of test group before and after treatment were 523.45±65.82 and 986.03±99.95 respectively with p-value <0.001, considered highly significant. Similarly, in control group mean ±SD before treatment and after treatment were 513.08±60.91 and 1034.62±31.61 respectively with p-value <0.001 and it is considered highly significant. The inter-group comparison concerning test group after treatment was not significant with p=0.05 suggesting that test formulation is as effective as the control in improving the quality of life in patients with dysmenorrhea (Table 06). The effect of test drug on quality of life is similar to that found in studies of Kannan P et al.33 Rehman et al.29 and Asma et al.22 with significant improvement in each study with p<0.01.

Table 6: SF-12-A comparison in two groups of patients studied

| SF-12   | Test Group | Control Group | Total  | P-value |
|---------|------------|---------------|--------|---------|
| BT      | 523.45±65.82 | 513.08±60.91  | 520.24±63.78 | 0.632 |
| AT      | 986.03±99.95 | 1034.62±31.61 | 1001.07±88.31 | 0.100 |

P value <0.001** <0.001** <0.001** -

The test used: Student t-test

Primary outcome measure

In the present study, 26 (89.7%) of the patients in the test group and 13 (100%) in the control group were relieved. Statistical analysis shows no significant difference (p=1.00) in alleviating subjective parameters in two groups of patients studied, suggesting that test drug is as effective as control (Table 07)

Secondary outcome measure

In the present study, 26 (89.7%) of the patients in the test group and 13 (100%) in the control group were relieved. Statistical analysis shows no significant difference (p=0.540) in improving objective parameters in two groups of patients studied, suggesting that test drug is as effective as control (Table 07)

Table 7: An outcome measure

| Outcome measure | Relieved | Not Relied | Total  | P-value |
|-----------------|---------|-----------|--------|---------|
| Primary outcome measure (POM) | 89.7 | 10.3 | 90.5 | 1 |
| Primary outcome measure (POM) | 100 | 0 | 7.1 | <0.001** |
| Secondary outcome measure: (SOM) Test group | 89.7 | 10.3 | 92.9 | 0.54 |
| Secondary outcome measure: (SOM) Control group | 100 | 0 | 7.1 | <0.001** |

Test used: Chi-Square/Fisher Exact Test

Limitations of this study are small sample size, validated scales for assessment of subjective parameters not used, differentiation of patients having primary or secondary dysmenorrhea was not done because of lack of basic investigations like USG. We recommend that studies with a larger sample size should be considered. Minimal investigations like USG pelvis should be done to differentiate the primary and secondary dysmenorrhea, and the effect of test drug on dysmenorrhea associated with different pathologies can be studied. Validated scales for assessment of subjective parameters should be incorporated.

CONCLUSION

The findings from the present study demonstrated that majoon murmaki is as effective as mfenamic acid in the management of usr tamth (dysmenorrhea). The effect of majoonmurmakkion usrtamth (dysmenorrhea) may be attributed to its properties like musakkinawjāh (analgesic), muhallilawrām (anti-inflammatory), mudirr-i-bawlwaḥayd
(diuretic and emmenagogue), *muffattih-i-sudad* (deobstruent) among others; also analgesic activity of furanoses-quiterpenes such as furanoelamanes,furanoeudes-manes and furanogermacranes present in the gum resin extract of myrrh. Hence, *Majoon murmaki* is a safe, herbal therapeutic option that can provide an alternate management option with no adverse events as caused by conventional treatments in *usre tams* (dysmenorrhea).

**ACKNOWLEDGEMENT**

Authors acknowledge the immense help received from the scholars whose articles are cited and included in references of this manuscript. The authors are also grateful to authors / editors / publishers of all those articles, journals and books from where the literature for the study has been reviewed and discussed.

**Conflict of interest:** None

**Financial support:** National Institute of Unani Medicine

**REFERENCES**

1. Mittal R. Medical management of dysmenorrhea. Int J Adv Res Ideas Innov Tech 2019; 5(1): 5-8.
2. Gebeeyehu MB, Mekuria AB, Tefera YG, Andarge DA, Debay YB, Bejiga GS, et al. Prevalence, impact, and management practice of dysmenorrhea among university of Gondar students, northwestern Ethiopia: a cross-sectional study. Int J Reprod Med 2017; 2017:1-8.
3. Franjie S. Menstrual pain. J Gynecol Res Obstet 2019; 5(2): 31-33.
4. De Sanctis V, Soliman A, Bernasconi S, Bianchin L, Bona G, Bozzola M. Definition and self-reported pain intensity in adolescents with dysmenorrhea: A debate report. Rivista Italiana di Medicinadell’Adolescenza. 2016;14(2):5-11.
5. Mohapatra D, Mishra TA, Behera M, Panda PR. A study of relation between body mass index and dysmenorrhea and its impact on daily activities of medical students. Asian J Pharm Clin Res 2016;9(3):297-9.
6. Chen CX, Barrett B, Kwekkeboom KL. Efficacy of oral ginger (Zingiber officinale) for dysmenorrhea: a systematic review and meta-analysis. Evid Based Complement Altern Med 2016; 2016:1-10.
7. Razi AMZ. Kitab- al-hawi. Vol -IX. New Delhi: CCRUM;2001.
8. Arzani MA. Qarabadeen qadri. New Delhi: CCRUM;2009.
9. Khan MA, Kabeeruddin M. Akseereazam (Al-akseer), New Delhi: Idarae Kitab-ul-shifa; 2011.
10. Raffiquddin M. Kanzul adviae mufrada. Aligarh: University Publication Unit: sarfraz house AMU; 1985.
11. Germano A, Occhipinti A, Barbero F, Maffei ME. A pilot study on bioactive constituents and analgesic effects of Myrliq, a Commiphora myrrha extract with a high furanodiene content. Germano A, Occhipinti A, Barbero F, Maffei ME. A pilot study on bioactive constituents and analgesic effects of Myrliq, a Commiphora myrrha extract with a high furanodiene content. BioMed Res Int 2017; 2017:1-11.
12. Sakpal TV. Sample size estimation in a clinical trial. Perspec Clin Res 2010; 1(2):67-69.
13. Yang M, Chen X, Bo L, Lao L, Chen J, Yu S, et al. Moxibustion for pain relief in patients with primary dysmenorrhea: A randomized controlled trial. PLoS One. 2017; 12(2): e0170952.
14. Rahnama P, Montazeri A, Huseini HF, Kianbakht S, Naseri M. Effect of Zingiber officinale R. rhizomes(ginger) on pain relief in primary dysmenorrhea: a placebo randomized trial. BMC Complement Altern Med 2012; 12:92.
15. Nahid K, Fariborz M, Atoolah G, Solokian S. The effect of an Iranian herbal drug on primary dysmenorrhea: a clinical controlled trial. J Midwifery Women’s Health 2009;54(5):401-4.
16. Salmalian H, Saghebi R, Moghadamnia AA, Bijani A, Faramarzi M, Amiri FN, et al. Comparative effect of thymus Vulgaris and ibuprofen on primary dysmenorrhea: A triple-blind clinical study. Casp J Intern Med 2014;5(2):82.
17. Liu C, Xie JP, Wang LP, Liu YQ, Song JS, Chen YY, et al. A randomized controlled trial of single point acupuncture in primary dysmenorrhea. Pain Med 2014;15(6):910-20.
18. Shirvani MA, Motahhari-Tabari N, Alipour A. The effect of mefenamic acid and ginger on pain relief in primary dysmenorrhea: a randomized clinical trial. Arch Gynecol Obstet 2015;291(6):1277-81.
19. Han SH, Hur MH, Buckle J, Choi J, Lee MS. Effect of aromatherapy on symptoms of dysmenorrhea in college students: A randomized placebo-controlled clinical trial. J Altern Complement Med 2006;12(6):535-41.
20. Jaafarpour M, Hatefi M, Khani A, Khajavikhan J. Comparative effect of cinnamon and ibuprofen for treatment of primary dysmenorrhea: a randomized double-blind clinical trial. JCIR 2015;9(4): 4-7.
21. Azima S, Bakhshayesh HR, Kaviani M, Abbasnia K, Sayadi M. Comparison of the effect of massage therapy and isometric exercises on primary dysmenorrhea: a randomized controlled clinical trial. J Pediatr Adolesc Gynecol 2015;28(8):486-91.
22. Asma K, Sultana A, Rahman K. A single-blind randomized comparative study of asafoetida vs mefenamic acid in dysmenorrhea, associated symptoms and health-related quality of life. J Herb Med 2017; 9:21-31.
23. Molins-Cubero S, Rodríguez-Blanco C, Oliva-Pascual-Vaca A, Heredia-Rizo AM, Boscá-Gandia JJ, Ricard F. Changes in pain perception after pelvis manipulation in women with primary dysmenorrhea: a randomized controlled trial. Pain Med 2014;15(9):1455-63.
24. Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan–naproxen: two randomized controlled trials. Obstetr Gynecol 2009;114(1):106-13.
25. Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B, Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstetr Gynecol 1999;94(4):504-8.
26. Chiu MH, Hsieh HR, Yang YH, Chen HM, Hsu SC, Wang IH. Influencing factors of dysmenorrhea among hospital nurses: a questionnaire survey in Taiwan. BMJ 2017;7(12):1-8.
27. Malmstrom K, Kotey P, Cihanowitz N, Daniels PJ. Analgesic efficacy of etoricoxib in primary dysmenorrhea: a randomized controlled clinical trial. J Pediatr Adolesc Gynecol 2009;12(1):7-12.
28. Atallah M, Akbari SA, Mojtab F, Majid HA. Effects of wheat germ extract on the severity and systemic symptoms of primary dysmenorrhea: a randomized controlled clinical trial. Iranian Red Crescent Med J 2014; 16(8):1-7.
29. Rehman H, Begum W, Anjum F, Tabasum F, Zahid S. Effect of rufibruc (Rheum emodi) in primary dysmenorrhea: a single-blind randomized controlled trial. J Complement Integr Med 2015;12(1):61-9.
30. Motahhari-Tabari N, Shirvani MA, Alipour A. Comparison of the effect of stretching exercises and mefenamic acid on the reduc-
tion of pain and menstruation characteristics in primary dysmenorrhea: a randomized clinical trial. Oman Med J 2017;32(1):47.
31. Shaviv H, Rosen DJ, Ezra Y. Dysmenorrhea: A randomized controlled clinical trial evaluating a novel treatment approach. Cogent Med 2018; 5 (1): 1-12.
32. Fletcher HM, Dawkins J, Rattray C, Wharfe G, Reid M, Gordon-Strachan G. Morinda citrifolia (Noni) as an anti-inflammatory treatment in women with primary dysmenorrhea: a randomised double-blind placebo-controlled trial. Obstet Gynecol Int 2013;2013:1-6.
33. Uysal G, Akkaya H, Cagli F, Tutus S, Tayyar AT. A comparison of two different oral contraceptives in patients with severe primary dysmenorrhea. J Obstet Gynaecol 2018;38(6):828-32.
34. Kannan P, Chapple CM, Miller D, Claydon-Mueller L, Baxter GD. Effectiveness of a treadmill-based aerobic exercise intervention on pain, daily functioning, and quality of life in women with primary dysmenorrhea: A randomized controlled trial. Contemp Clin Trials 2019; 81:80-6.
35. Harada T, Momoeda M, Terakawa N, Taketani Y, Hoshiai H. Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertility Sterility 2011;95(6):1928-31.
36. Kartal YA, Akyuz EY. The effect of diet on primary dysmenorrhea in university students: A randomized controlled clinical trial. PJMS 2018; 34(6): 1478-82.